## IN THE CLAIMS

## Current Listing Of Claims:

- (Currently Amended) A method, comprising: 1. identifying an infarct region within the ventricle of a human subject; and delivering at least one structurally reinforcing component to the infarct region, wherein the structurally reinforcing component comprises cells a non-antigenic cell line comprising  $\alpha$  -1,3-galactosyltransferase (GGTA1) knock-out swine cells to the infarct region within the ventricle of the human subject.
- 2. (Cancelled)
- (Currently Amended) The method of claim 1, wherein both chromosomal copies of 3. the at least one gene a gene for  $\alpha$  -1,3-galactosyltransferase (GGTA1) knock-out swine cells have been disrupted.
- 4. (Cancelled)
- (Currently Amended) The method of claim 1, wherein delivering at least one 5. structurally reinforcing agent further comprising delivering at least one structurally reinforcing agent to the infarct region to increase increases the modulus of elasticity of the infarct region.
- (Original) The method of claim 1, wherein the cells replace damaged cells in and 6. around the infarct region.
- (Currently Amended) The method of claim 1, wherein delivery of at least one 7. structurally reinforcing agent the non-antigenic cell line occurs within 2 weeks of a myocardial infarction (MI).

8. (Currently Amended) The method of claim 1, further comprising at least one nucleic acid encoding a detectable polypeptide carried by the cells, the at least one nucleic acid being operably linked to a promoter wherein a nucleic acid encoding a detectable polypeptide carried by the non-antigenic cell line is operably linked to a promoter.

## 9-18. Cancelled

- 19. (Currently Amended) A method, comprising:
  identifying an infarct region within the <u>a</u> ventricle of a subject;
  applying a pacing algorithm for CRT (cardiac resynchronization therapy) treatment,
  or normal pacing therapy to the ventricle to pre-excite the infarct region to unload the
  infarct region from mechanical stress; and
  delivering <u>an</u> at least one structurally reinforcing component to the infarct region <u>after</u>
  applying the pacing therapy.
- 20. (Currently Amended) The method of claim 19, wherein the at least one structurally reinforcing component comprises α-1,3-galactosyltransferase (GGTA1) knock-out swine cells.
- 21. (Currently Amended) The method of claim 20, wherein the cells comprise a genetically engineered cell in which at least one gene encoding a polypeptide comprising an antigenic determinant which is recognized by a desired recipient subject or at least one gene which encodes a protein associated with the synthesis of a molecule comprising an antigenic determinant recognized by the desired recipient subject has been disrupted 19, wherein the pacing therapy comprises a bradycardia pacing algorithm.

Application No. 10/802,955

Amendment filed: October 14, 2005 Reply to Office Action of May 17, 2005

22. (Currently Amended) The method of claim 21, wherein the cells at least one structurally reinforcing component comprise α 1,3-galactosyltransferase (GGTA1) knock-out swine cells 19, further comprising modifying the pacing therapy based upon sensor measurements.

23-62. Canceled